Study of Pembrolizumab in Participants With Advanced Solid Tumours

Trial Purpose

In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumours who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).

NATIONAL TRIAL REFERENCE NUMBER

NCT02628067

EudraCT

2015-002067-41

EU CT

2022-500397-34-00

When speaking to your doctor or clinical trial representative, please have the trial reference number available.

Resources

Eligibility

Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.

Conditions

Advanced Cancer, Advanced Solid Tumours, Advanced Solid Tumours, Anal Cancer, Anal Carcinoma, Bile Duct Cancer, Biliary Cancer, Biliary Cancer, Carcinoid Tumor, Cervical Cancer, Cervical Carcinoma, Cholangiocarcinoma, Colorectal Carcinoma, Endometrial Cancer, Endometrial Carcinoma, Mesothelioma, Neuroendocrine Tumor, Parotid Gland Cancer, Salivary Cancer, Salivary Gland Cancer, Salivary Gland Carcinoma, Small Cell Lung Cancer, Small Cell Lung Carcinoma, Solid Tumors, Solid Tumour, Thyroid Cancer, Thyroid Carcinoma, Vulvar Cancer, Vulvar Carcinoma, Vulvar Carcinoma

Age Range

18+

Sex

All

About The Trial

Trial Phase

Trial Phase 2

Tests the medicine or vaccine in approximately 100 to 500 volunteers. In the case of medicines, volunteers usually have the disease or condition the investigational medicine is designed to treat. In vaccine studies, the volunteers are usually healthy.

Trial start and end dates

Actual study start date 18 December 2015
Estimated primary completion date 2 October 2026
Estimated study completion date 2 October 2026

Trial locations

Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.

What can you do next?

If you think this clinical trial might be a good fit and you are interested in taking part, take the next step to see if you are eligible.

Discuss with your doctor or care team

Print this page with details about the trial or email it to your doctor to discuss the clinical trial during your next visit.

Get help talking with your doctor or care team

NATIONAL TRIAL REFERENCE NUMBER

NCT02628067

EudraCT

2015-002067-41

EU CT

2022-500397-34-00

When speaking to your doctor or clinical trial representative, please have the trial reference number available.

Taking part in a clinical trial is an important decision

If you are considering joining a clinical trial, first learn as much as you can about:

The investigational treatment that is being studied
What the risks and possible benefits are for participants

Talk to your doctor about the clinical trial before you decide to join.

Read our “What to Consider” page for more questions to ask and think about